anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Experiment is about the use of abrasion technic with dermaroller, equipped with a 0,25mm needle, applied on a vitiligo lesion. After that, a transplant with non cultured cell suspension (melanocytes and keratinocytes) will be applied to pacient 's skin scalp.
1530846 Anti-cancer agent from Staphylococcus epidermidis TOBISHI PHARMACEUTICAL CO Ltd 13 Sept 1977 [13 Sept 1976] 38218/77 Heading A5B An anti-cancer agent active against liquid and solid cancers (e.g. leukemia, sarcoma) is obtained by cultivating a new strain of Staphylococcus epidermidis designated as strain STF (Bikoken Deposit No. 3706, ATCC 31310). The strain is cultivated in culture medium containing assimilable sources of nitrogen, carbon and inorganic salts, preferably under aerobic conditions, and the active agent is present in the cell - free culture medium. It may be isolated by concentrating the medium (e.g. by evaporation under reduced pressure), separating resulting solid matter, redissolving this matter in water and fractionating the solution (e.g. on adsorptive gel, by ion-exchange chromatography or by use of a molecular sieve membrane), to give anti-cancer fractions (a) of molecular weight 1000-5000, and (b) of molecular weight 5000-10,000. The material is stable at 100C for 15 minutes and is negative in Ninhydrin, Ehrlich and Sakaguchi reactions. The solutions may be evaporated to give the agent in solid form. It may be administered as a purified cell-free culture fluid or as various oral, parenteral or suppository pharmaceutical forms with a suitable carrier.
Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as new treatment options in ovarian cancer. While there is now also evidence for the efficacy in the first line setting, they were initially studied in recurrent disease both as maintenance after chemotherapy but also as treatment on its own. The NOVA study was conducted in the maintenance setting of patients with recurrent high-grade serous ovarian-, tube or peritoneal cancer who had responded to platinum-based chemotherapy. In 2017 Tesaro opened an individual patient access program in Norway, and in July 2017 the first Norwegian patient was enrolled. We performed a retrospective observational study of patients treated with niraparib in the individual patient access program in Norway. The objective of the study is to provide preliminary efficacy and safety data in a rather unselected population of non-gBRCA patients with recurrent ovarian-, tube-, or peritoneal cancer.
Participants will receive OROS-MPH (Concerta® available in Switzerland as first-line treatment for ADHD). Dosages will be defined according to the Swiss Compendium. The psychiatrist (blinded during detention) will start with the smallest dosage (18 mg, Concerta®). The treatment will be monitored weekly the first month, and then monthly. The pharmacy of the Geneva University Hospitals will be in charge of over-encapsulating medications.
Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m\^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
Patients with locally advanced upper third gastric carcinoma will performed robotic assisted spleen-preserving No.10 lymph node dissections. After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
Based on the fact that a high incidence rate (14.2%) of rare tumor (incidence rate \<2.5/100,000) as defined in this study according to the National Cancer Registry data from National Cancer Center of China, as well as the current status of lacking guidelines and consensus of rare tumor treatment. We proposed this study "A Phase II, open label, non-randomized, multiple-arm, single-center clinical trial in patients with advanced rare solid tumors who failed to standard treatment", aims to evaluate the safety and efficacy of targeted drugs of specific tumor-driven genes in patients with advanced rare solid tumors with corresponding actionable alterations, as well as the safety and efficacy of immune checkpoint (PD-1) inhibitors in patients with advanced rare solid tumors without actionable alterations. Patients with advanced rare tumors who failed to standardized treatment carrying actionable alterations as "EGFR mutation (exon 19 deletion mutation, L858R replacement mutation), ALK gene fusion, ROS-1 gene fusion, C-MET gene amplification or mutation (D1010 mutation, 14 exon mutation, y1003 mutation), BRAF mutation, CDKN2A mutation, BRCA1/2 mutation, HER-2 mutation, HER-2 over expression/amplification, C-KIT mutation", will enroll targeted therapy arms and be given corresponding targeted drugs (Dacomitinib, Crizotinib). And patients without targeted alterations mentioned above will enroll PD-1 inhibitor arm and to be treated with Sintilimab. After acquired resistance patients treated with olaparib and palbociclib will receive combination treatment with durvalumab. After acquired resistance patients treated with vemurafenib will receive combination treatment with atezolizumab. The statistics of current study adopts Simon's two-stage Minimax design: In the first stage of clinical research, 12 subjects will be observed. If the number of CR + PR is less than 1, the trial will be terminated, otherwise, the group will continue to expand to 16 subjects. Therefore, in the first stage, there are 12\*5/(1-10%)=54 patients of targeted treatment group and 126 patients in the immunotherapy group, 180 patients totally in the first stage. If they all enter the second stage, the final target treatment group is 16\*5/(1-10%) = 72 patients and the immunotherapy group which has 168 patients which brings to a total of 240 patients. The sample size of the study shall be adjusted according to the interim analysis. Primary Endpoint of this study is objective response rate (ORR) in immunotherapy group and targeted therapy group assessed by Blinded Independent Central Review (BICR) and investigator. Secondary Endpoints are Progression-Free Survival (PFS) in the targeted treatment group assessed by Blinded Independent Central Review and investigator; PFS (RECIST 1.1) and iPFS (iRECIST) in the single drug immunotherapy group assessed by Blinded Independent Central Review and investigator; Duration of Response (DoR) in the targeted therapy and single immunotherapy groups assessed by the investigator; Durable Clinical Benefit (DCB) in the single drug immunotherapy group; Incidence of Adverse Events (AE) in subjects ect.
Eligible patients with hepatic or pulmonary oligometastatic adenocarcinoma of the pancreas must have received neoadjuvant FOLFIRINOX chemotherapy in cycles of 14 days, or other clinically indicated alternative. FOLFIRINOX is not a study treatment. Patients with pulmonary metastasis with tumor response or stable disease and a resectable primary tumor after the first 4 cycles can undergo resection of the primary tumor followed by resection of pulmonary metastases or vice versa, if feasible.Patients with hepatic metastasis with tumor response or stable disease and a resectable primary tumor can undergo explorative laparotomy and synchronous resection of the tumor and hepatic metastases, if feasible. In patients who undergo exploratory laparotomy and are deemed to have unresectable disease by the surgeon, the patient may receive 4 more cycles of neoadjuvant chemotherapy 2-4 week after surgery, before the patient will be re-evaluated for the eligibility for the Study Entry Screening.
PURPOSE:To obtain the title treating agent effective in inhibiting reverse transcriptase activity of retrovirus and suppressing the growth of the virus, by using oligosaccharides or polysaccharides having an S-oxoacid group bonded to a sugar-constituting carbon atom. via a low-molecular weight linking group, as active component. CONSTITUTION:The objective agent contains, as active component, natural or synthetic oligosaccharides, polysaccharides or their salts having at least one S-oxoacid group (e.g. -SO3H or -SO.OH) bonded to a sugar-constituting carbon atom. via a linking group (e.g. O, NH, S or CH2) having a low molecular weight (from 14-32). The active component is e.g. a natural saccharide having at least one hydrogen sulfuric acid ester group (-O-SO3H) derived from vegetable or microorganism or a saccharide produced by converting natural oligosaccharides or polysaccharides to a sulfuric acid ester (e.g. dextran sulfate or arginic acid sulfate). The dose of the agent to attain a blood concentration effective in exhibiting antiviral activity is 0.2-200mg/kg, especially 0.5-100mg/kg.
NEW MATERIAL:A peptide expressed by formula I [either of X and Y is single bond or Asp, Glu, Lys or bifunctional group expressed by formula II (n is an integer of 1-17), peptide residue of 2-10 amino acid residues, etc.; Z is hydroxyl or amino group; mercapto groups of the respective Cys groups may mutually link to form disulfide bonds in Cys-Cys of the amino acid sequence]. USE:A remedy for myasthenia gravis. PREPARATION:For example, a styrene-divinylbenzene copolymer hazing 4-[N-(tert-butoxycarbonyl)glycyloxymethyl]phenylacetamidomethyl group is reacted with amino acids having protected amino group according to the amino acid sequence of a peptide from the C-terminal side to remove the amino- protecting groups. The above-mentioned operations are repeated to synthesize a peptide chain. The resultant peptide is then eliminated from the polymer to afford the aimed peptide expressed by formula 1.
The invention relates to a doxofylline-containing liquid injection used for treating bronchiectasis, and provides the doxofylline with higher concentration. The injection comprises doxofylline, a water solvent, and a pH value regulating agent. The injection comprises the following components by weight percentage: 1 to 4 percent of the doxofylline, and 0.01 to 5 percent of the pH value regulating agent. The injection enriches specifications of the prior doxofylline injection, and brings convenience to the clinical application. The invention also provides a preparation method and a quality control method for the doxofylline liquid injection. Relevant materials in the doxofylline injection can be determined by an HPLC method to improve the product controllability.
The present invention relates to isolated MEKK1 proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to use such proteins to regulate apoptosis. The invention provides active fragments of MEKK1 proteins that are generated upon cleavage of MEKK1 with a caspase protease. These active fragments are capable of stimulating apoptosis. Moreover, the invention provides protease-resistant forms of MEKK1 proteins, that are resistant to cleavage by caspase proteases and that are capable of inhibiting apoptosis. Still further, the invention provides methods for generating an active fragment of MEKK1, methods of identifying modulators of the apoptotic activity of an active fragment of MEKK1 and methods of identifying modulators of caspase-mediated cleavage of MEKK1.
The invention relates to a C7 and C10 modified 1-dehydroxyl taxol analogue and a preparation method thereof. The structural formula of the compound is shown in the specification, wherein R1 is a C1-C8 linear chain or branched alkyl group, a C3-C6 cycloalkyl group, a phenyl group, or a 5--membered or 6-membered aromatic ring containing nitrogen, sulphur or oxygen; and R2 is a C1-C8 linear chain or branched alkyl group or a C3-C6 cycloalkyl group. The structural formula of the analogue is shown in the above formula. In the preparation method, the target product C7 and C10 modified 1-dehydroxyl taxol analogue is synthesized and obtained based on 1-dehydroxyl baccatin VI as a raw material. The obtained product has bioactivity in the aspect of anticancer and has an application prospect in the aspect of drug resistance of taxol. The preparation method has the characteristics of good selectivity, simple post-treatment and high yield.
Participant received a single dose of TPIP 112.5 micrograms (μg) via oral inhalation on Day 1. The participant then entered into a 16-week Extended Use Treatment (EUT) Period during which TPIP, administered via oral inhalation, was titrated up to a mean daily dose of 320 μg.
Hiccup relates to that a sound is made by sudden close of glottis after hurried inhalation caused by diaphragm myospasm, and is generally called hiccough. An effective prescription provided by the invention for treating the hiccup adopts Chinese herbal medicines as raw materials. Juice is extracted by a traditional medicine decocting method and is orally taken. The effective prescription is an adequate remedy for the disease according to the nosogenesis, has no toxic effects or side effects, and has unique treating effects for the hiccough. The effective prescription for treating the hiccup is researched and demonstrated repeatedly for a plurality of years. Based on numbers of cured patients for decades of years, the total effective rate is 92% and the curative rate is 90% by clinical curative effect observation. The effective prescription for treating the hiccup has a strong function of relieving the myospasm and has significant curative effects for the hiccough. The effective prescription can enhance human immunologic functions. The effective prescription has short curative period, rapid effectiveness, good consolidation and taking convenience, and is an only holistic therapy effective prescription for treating the hiccup.
Healthy patients will then undergo at least a 2-week course of 81mg of Bayer Aspirin per oral daily, followed by platelet function testing. The patients will then undergo a washout period of 2 weeks, followed by another 2-week course of 81mg Vazalore Aspirin per oral daily, followed by a second round of platelet function testing.
A toothbrush having a handle portion, a shank portion and a head portion. A channel extends longitudinally through the handle portion, the shank portion and terminates in the head portion. The channel is sized to slidably receive one or more toothpaste pellet formulated to effervesce when exposed to water or saliva. An aperture extends transverse through the head portion providing fluid communication into the channel. A one-way gate is disposed within the channel permitting a toothpaste pellet to pass into the head portion, and to prevent the toothpaste pellet from passing out of the head portion. A handle cap is removably attached to a lower end of the handle portion. The head portion and shank portion may be received within a head cap that removably attaches to the handle portion.
PURPOSE: To examine if changes in hemodynamic measures during an orthostatic challenge were associated with progression of age-related macular degeneration (AMD) over a 4-year period in The Irish Longitudinal Study on Ageing.
METHODS: Participants with AMD who underwent an active stand (AS) test at wave 1 (2009/2010) and retinal photographs at both wave 1 and wave 3 (2014/2015) were included (N = 159: 121 with no AMD progression and 38 with progression). Beat-to-beat hemodynamic data were non-invasively collected using a Finometer MIDI device during the AS at wave 1, recording systolic blood pressure (sBP), diastolic blood pressure (dBP), mean arterial pressure (MAP), and heart rate. Cardiac output, stroke volume, and total peripheral resistance (TPR) were derived from these measures. Baseline characteristics were compared between groups with and without AMD progression. Mixed-effects linear regression models were used to assess the association between changes in hemodynamic parameters during the AS and AMD progression, controlling for known AMD-associated risk factors.
RESULTS: At baseline, increasing age and lower dBP were significantly associated with AMD progression. Mixed-effects models for the period between standing and 10 seconds post-stand revealed significant associations with AMD progression with a steeper drop in dBP and a slower drop in TPR. Between 10 and 20 seconds post-stand, AMD progression was significantly associated with less pronounced reduction in heart rate.
CONCLUSIONS: These observational data suggest that impaired hemodynamic responses within the first 20 seconds of orthostasis may be associated with the progression of AMD.
Participants received the first intravenous (IV) infusion of liquid alpha1-proteinase inhibitor (human) 120 milligrams per kilogram (mg/kg), based on body weight on Day 1, followed by second liquid alpha1-proteinase inhibitor (human) dose of 120 mg/kg based on body weight, on Day 8 (second dose was not mandatory and was given at the principal investigator's \[PI\] discretion). Participants also received all standard of care interventions while hospitalized, from Day 1 to Day 29.
Most recurrences of lung cancer (LC) occur within 3 years after surgery, but the underlying mechanism remains unclear. Here, we collect LC tissues with shorter (<3 years, recurrence group) and longer (>3 years, non-recurrence group) recurrence-free survival. By using 16S sequencing, we find that intratumor microbiome diversity is lower in the recurrence group and butyrate-producing bacteria are enriched in the recurrence group. The intratumor microbiome signature and circulating microbiome DNA can accurately predict LC recurrence. We prove that intratumor injection of butyrate-producing bacteria Roseburia can promote subcutaneous tumor growth. Mechanistically, bacteria-derived butyrate promotes LC metastasis by increasing expression of H19 in tumor cells through inhibiting HDAC2 and increasing H3K27 acetylation at the H19 promoter and inducing M2 macrophage polarization. Depletion of macrophages partially abolishes the metastasis-promoting effect of butyrate. Our results provide evidence for the cross-talk between the intratumor microbiome and LC metastasis and suggest the potential prognostic and therapeutic value of the intratumor microbiome.
The potential for oil spills poses a threat to marine organisms, the toxicity of which has been attributed primarily to polycyclic aromatic compounds (PACs). Predictive tools such as the target lipid model (TLM) have been developed to forecast and assess these risks. The aim of the present study was to characterize the cardiotoxicity of 10 structurally diverse PACs in American lobster (Homarus americanus) larvae by assessing heart rate following a 48 h exposure in a passive dosing system, and subsequently use the TLM framework to calculate a critical target lipid body burden (CTLBB) for bradycardia. Exposure to 8 of the 10 PACs resulted in concentration-dependent bradycardia, with phenanthrene causing the greatest effect. The TLM was able to effectively characterize bradycardia in American lobsters, and the cardiotoxic CTLBB value determined in this study is among the most sensitive endpoints included in the CTLBB database. This study is one of the first to apply the TLM to a cardiac endpoint and will improve predictive models for assessing sublethal impacts of oil spills on American lobster populations.
1,224,589. Complex iron salts. G. GERGELY. 6 Oct., 1969, No. 48936/69. Heading C2C. [Also in Division C6] Complex iron salts are obtained by reacting an iron salt of an unsaturated dicarboxylic acid (with up to 6 C atoms) with alkali metal or alkaline earth metal salts of carboxylic acids such as sodium nitrate or sodium glycinate. Ferrous fumarate is an example and the components are mixed in finely ground form and 5-8% of water added.
Animal and human studies have not shown any adverse effects of dofetilide on conduction velocity. No effect on AV nodal conduction following dofetilide treatment was noted in normal volunteers and in patients with 1 stdegree heart block. Patients with sick sinus syndrome or with 2 ndor 3 rddegree heart block were not included in the Phase 3 clinical trials unless a functioning pacemaker was present. Dofetilide has been used safely in conjunction with pacemakers (53 patients in DIAMOND studies, 136 in trials in patients with ventricular and supraventricular arrhythmias). 

Dofetilide Capsules 0.125 mg, 0.25 mg and 0.5 mg contain FD&C Yellow No. 6 as a color additive.
A personalized and distributed decision support system in hospital information systems has for a novelty a distribution feature that includes a central (100) and a distributed (104) decision support system where the central decision support system (100) does not store data from clients, it creates the basic template of the program that transmits to the distributed system (104). Distributed system (104) also has the feature of personalization as innovative in the sense that it contains a personalized model (107) of scripts that is formed on the basis of a distributed template program by the central decision support system (100) and based on input data and is also subject to change. Central system (100) consists of: a machine script (101) that processes patient object data, a function library (102) called by a machine script (101), a predictive model (103) that determines a function form and personal function coefficients, and a distributed decision support system (104) consists of a personalized model (107) on which also has an internal database (106) as well as internet inputs/outputs (105). The central decision support system (100) communicates with the expert modules (108) bidirectionally, after which it is passed in the iterations and collaboration of the expert modules (108) in order to make the best decision for the patient. And communication between the central system (100) and distributed decision support systems (104) is two- way. The predictive model (102) can be a linear regression model, an artificial neural network, or a polynomial function while the coefficients of the predictive model (102) are adapted to patients and their objects. Personal models (103) are created by the integration of the predictive model (102) and the personal coefficients housed in the internal database of (106) application servers, patients.
Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were not diagnosed with glaucoma.
One useful cancer treatment approach is activating the patient's immune response against the tumor. In this regard, immunotherapy (IT) based on immune checkpoint blockers (ICBs) has made great progress in the last two decades. Although ITs are considered a novel approach to cancer treatment and have had good results in preclinical studies, their clinical success has shown that only a small proportion of treated patients (about 20%) benefited from them. Moreover, in highly progressed tumors, almost no acceptable response could be expected. In this regard finding the key molecules that are the main players of tumor immunosuppression might be helpful in overcoming the possible burdens. Hypoxia is one of the main components of the tumor microenvironment (TME), which can create an immunosuppressive microenvironment in various ways. For example, hypoxia is one of the main factors of programmed cell death ligand-1 (PD-L1) upregulation in tumor-infiltrating Myeloid-Derived Suppressor Cells (MDSCs). Therefore, hypoxia can be targeted to increase the efficiency of Anti-PD-L1 IT and has become one of the important issues in cancer treatment strategy. In this review, we described the effect of hypoxia in the TME, on tumor progression and immune responses and the challenges created by it for IT.